Literature DB >> 8642568

Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides.

S J Coutts1, T A Kelly, R J Snow, C A Kennedy, R W Barton, J Adams, D A Krolikowski, D M Freeman, S J Campbell, J F Ksiazek, W W Bachovchin.   

Abstract

A series of prolineboronic acid (boroPro) containing dipeptides were synthesized and assayed for their ability to inhibit the serine protease dipeptidyl peptidase IV (DPPIV). Inhibitory activity, which requires the (R)-stereoisomer of boroPro in the P1 position, appears to tolerate a variety of L-amino acids in the P2 position. Substitution at the P2 position which is not tolerated include the D-amino acids, alpha,alpha-disubstituted amino acids, and glycine. Specificity against DPPII and proline specific endopeptidase is reported. A correlation between the ability to inhibit DPPIV in cell culture and in the human mixed lymphocyte reaction is demonstrated. A synthesis of prolineboronic acid is reported as well as conditions for generating the fully unprotected boronic acid dipeptides in either their cyclic or acyclic forms.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8642568     DOI: 10.1021/jm950732f

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  24 in total

Review 1.  The versatility of boron in biological target engagement.

Authors:  Diego B Diaz; Andrei K Yudin
Journal:  Nat Chem       Date:  2017-07-25       Impact factor: 24.427

2.  A method for the deprotection of alkylpinacolyl boronate esters.

Authors:  Jing Sun; Michael T Perfetti; Webster L Santos
Journal:  J Org Chem       Date:  2011-04-07       Impact factor: 4.354

3.  Selective fluorescence probes for dipeptidyl peptidase activity-fibroblast activation protein and dipeptidyl peptidase IV.

Authors:  Koon Siew Lai; Nan-Hui Ho; Jonathan D Cheng; Ching-Hsuan Tung
Journal:  Bioconjug Chem       Date:  2007-05-10       Impact factor: 4.774

4.  Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease.

Authors:  Angela Pennisi; Xin Li; Wen Ling; Sharmin Khan; Dana Gaddy; Larry J Suva; Bart Barlogie; John D Shaughnessy; Nazneen Aziz; Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2009-04-08       Impact factor: 6.998

5.  Cleavage Specificity of Mycobacterium tuberculosis ClpP1P2 Protease and Identification of Novel Peptide Substrates and Boronate Inhibitors with Anti-bacterial Activity.

Authors:  Tatos Akopian; Olga Kandror; Christopher Tsu; Jack H Lai; Wengen Wu; Yuxin Liu; Peng Zhao; Annie Park; Lisa Wolf; Lawrence R Dick; Eric J Rubin; William Bachovchin; Alfred L Goldberg
Journal:  J Biol Chem       Date:  2015-03-10       Impact factor: 5.157

6.  Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase.

Authors:  Sarah E Poplawski; Jack H Lai; Youhua Li; Zhiping Jin; Yuxin Liu; Wengen Wu; Yong Wu; Yuhong Zhou; James L Sudmeier; David G Sanford; William W Bachovchin
Journal:  J Med Chem       Date:  2013-04-29       Impact factor: 7.446

7.  DPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis.

Authors:  Marian C Okondo; Darren C Johnson; Ramya Sridharan; Eun Bin Go; Ashley J Chui; Mitchell S Wang; Sarah E Poplawski; Wengen Wu; Yuxin Liu; Jack H Lai; David G Sanford; Michael O Arciprete; Todd R Golub; William W Bachovchin; Daniel A Bachovchin
Journal:  Nat Chem Biol       Date:  2016-11-07       Impact factor: 15.040

8.  Using substrate specificity of antiplasmin-cleaving enzyme for fibroblast activation protein inhibitor design.

Authors:  Kyung N Lee; Kenneth W Jackson; Simon Terzyan; Victoria J Christiansen; Patrick A McKee
Journal:  Biochemistry       Date:  2009-06-16       Impact factor: 3.162

9.  Peptide and Peptide-Like Modulators of 20S Proteasome Enzymatic Activity in Cancer Cells.

Authors:  Carlos García-Echeverría
Journal:  Int J Pept Res Ther       Date:  2006-03-04       Impact factor: 1.931

10.  Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma.

Authors:  Robert M Eager; C Casey Cunningham; Neil N Senzer; Joe Stephenson; Stephen P Anthony; Steven J O'Day; Gary Frenette; Anna C Pavlick; Barry Jones; Margaret Uprichard; John Nemunaitis
Journal:  BMC Cancer       Date:  2009-07-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.